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Despite ongoing research efforts and attempts to bring new drugs into trial, the prognosis for brain tumors remains
poor. Patients with the most common and lethal intracranial neoplasia, glioblastoma multiforme (GBM), have an
average survival of one year with combination of surgical resection, radiotherapy and temozolomide. One of the
main problems in the treatment of GBM is getting drugs across the blood brain barrier (BBB) efficiently. In an
attempt to solve this problem, there are ongoing experimental and clinical trials to deliver drugs within stem cells.
The purpose for this method is the ease by which stem cells home to the brain. This review discusses the
experimental and clinical applications of stem cells for GBM. We also discuss the different properties of stem cells.
This information is important to understand why one stem cell would be advantageous over another in cell
therapy. We provide an overview of the different drug delivery methods, gene-based treatments and cancer
vaccines for GBM, including the stem cell subset.
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The prognosis for patients with brain tumors, in particu-
lar glioblastoma, remains poor. This poor prognosis
could be explained by the hindrance to get drugs to the
brain for achieving efficacious levels. Stem cells have
shown tremendous promise for almost all fields of medi-
cine including drug delivery. The application of stem
cells as a cellular vehicle to deliver drugs to the brain
has been noted because stem cells can cross the blood
brain barrier (BBB) and can exert pathotropic effects,
which attests to their ability to home to tumor sites.
Mesenchymal stem cells (MSCs) and neural stem cells
(NSCs) have been used in trials to deliver prodrugs to
tumors [1,2]. However, since MSCs can also support
tumor growth, this represents a major disadvantage for
the application of MSCs in drug delivery to target tu-
mors [3]. Despite this disadvantage, MSCs have a unique
advantage in that they can be available upon demand,
generally referred to as a source of off-the-shelf cells.
This ease of availability is primarily due to their ability
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unless otherwise stated.injection across an allogeneic barrier. It is unclear if
NSCs have a similar property for use on demand or if
they require matching at the major histocompatibility
complex class II. This review article discusses the differ-
ent issues associated with the application of stem cells as
vehicles of drug delivery, using glioblastoma as a repre-
sentative indication.Sources of stem cells - advantages/disadvantages
Embryonic (ESC), fetal and adult stem cells are intensely
studied for their ability to differentiate into neuronal
cells by in vitro methods, and are studied for their use in
neurological disorders [4,5]. Each class of stem cell pos-
sesses advantages and disadvantages for treatment of
neural disorders. ESCs are derived from the inner cell
mass of the blastocyst and can be differentiated in vitro
into all cell types. Theoretically, the intrinsic ability of
ESCs to form all types of neural tissues makes them su-
perior to other stem cells. Similarly, induced pluripotent
stem cells (iPSCs), which are generated through genetic
manipulation of somatic cells, have the potential to form
all types of cells including those within the neuronal and
glial lineages [6]. The main disadvantage of ESCs and
iPS is their ease in spontaneous transformation. Otherl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the inefficiency to generate iPSCs.
The scientific disadvantages of ESCs and iPS led to in-
creased interest in cell replacement strategies with adult
stem cells (ASCs). More importantly, the ASCs have
prospects for transplantation without ethical dilemmas.
Regarding brain repair, ASCs can be effective with NSCs,
MSCs, hematopoietic stem cells (HSCs) and stem cells
from umbilical cord blood (UCB). Although still in ex-
perimental phase, the experimental evidence indicated
that some or all of the aforementioned stem cells can
differentiate into neurons and glia. There are distinct ad-
vantages of some stem cell sources over others.
NSCs are multipotent cells found within selected re-
gions of the adult brain. NSCs can differentiate into cells
of all neural lineages [7,8]. Two neurogenic areas of the
brain where NSCs reside are the subventricular zone
(SVZ) of the lateral ventricles and the subgranular layer of
the hippocampal dentate gyrus [9]. Physiologically, NSCs
are responsible for neocortical neurogenesis to help re-
place damaged tissue [9]. This regenerative capacitance is
outweighed by the rate of neural degeneration and the
amount of damaged tissues in neurodegenerative condi-
tions. An example of this imbalance could be seen in trau-
matic brain injury. Subacute NSC therapy following
traumatic brain injury led to cells incorporating and
remaining in the tissues two weeks after transplantation
[10]. The transplanted NSCs have been shown to improve
the motor function of the experimental animals [10]. A
major disadvantage to the utilization of NSCs is the diffi-
culty of harvesting and isolation from an intact brain tis-
sue. Human NSCs can be generated from differentiated
ESC, iPSCs, fetal tissues sources and cadavers. None of
these sources might be able to produce adequate number
of NSCs for widespread clinical implementation.
MSCs are heterogeneous, multipotent cells found in
several adult tissues including bone marrow (BM) and
adipose. MSCs can form cells of all germ layers [11]. In
BM, MSCs are found around the central sinus where
they can function as “gate-keeper” cells. At this site, the
MSCs contact the abluminal region of the sinus. The
presence of MSCs around the central sinus is significant
to the protection of BM functions [12]. The method by
which MSCs protect the BM might be important to ex-
trapolate to other organs such as neural protection ef-
fects of MSCs.
Intravenous administration of allogeneic MSCs can
promote functional recovery and brain repair in experi-
mental ischemic stroke [13]. Due to the ease of harvest-
ing and expanding MSCs, they can be easily available
from both allogeneic and autologous sources for trans-
plantation to patients. A major advantage of MSCs to be
transplanted across allogeneic barrier makes MSCs an
attractive alternative for neural repair.BM-derived HSCs were reported to have neurogenic
potential [14]. HSCs are multipotent cells with their
main purpose to replenish the body’s immune and blood
cells [15]. HSCs can be selected from the adult BM using
well-defined markers. However, there are constraints for
clinical application; in particular their low frequency in
the BM, and their inability to be expanded. More im-
portantly, there is no clear data that HSCs can generate
neural cells. Overall, HSCs represent a less favorable
source for neural repair.
UCB is a rich source of HSCs. The HSCs are function-
ally more immature as compared to similar cells in the
adult BM [16]. MSCs can be isolated in the Wharton
jelly of the cord and, to a lesser extent from UCB. If
cord-derived MSCs can generate neurons or can be effi-
cient in neural repair, this would be a major advantage
because there is no risk to the donor since the cord
would be otherwise discarded. Regarding hematopoietic
replacement with UCB cells, there is a limitation be-
cause of the low volume of blood. This would provide
inadequate number of HSCs for transplantation.
Drug delivery - blood brain barrier (BBB)
The brain has limited regenerative capacity sufficient
only to replace modest numbers of lost cells [17,18]. The
brain has shown a surprising ability for spontaneous re-
pair in patients with stroke [19]. Accordingly, special
biological protections exist to protect this vital organ,
making the brain a difficult target for delivery of thera-
peutics. These include the hard barrier created by the
skull, three meninges membranes of varying thickness/
toughness, cerebrospinal fluid, and the BBB. The brain is
well-protected by the BBB. The BBB is a biological fort-
ress created primarily by a sheet of tightly knit endothe-
lial cells. The cellular junctions are tight so that even
small molecules have difficulty to cross the BBB. The
BBB effectively seals off the brain from the rest of the
body and enables strict selectivity in what crosses into
the brain. In practice, this means that most therapeutics
will not pass through the BBB. This can be problematic
even for diseases affecting tissues other than the brain.
For example, secondary tumors arising after breast can-
cer treatment can be found in the brain. This is thought
to occur because most anticancer treatments do not pass
through the BBB, leaving metastasized cells to reside in
the brain. At a later date, they can emerge from quies-
cence to form deadly tumors [20].
Stem cells have been proposed as a cellular vehicle to
deliver therapeutic agents to the brain. Due the difficulty
of treating glioblastoma this type of cancer forms a basis
to test if drugs delivered within stem cells can be effect-
ive in targeting the cancer cells (Table 1). There are a
number of strategies by which the stem cells are deliv-
ered to facilitate passage of therapeutics through the
Table 1 Stem cells in drug delivery to treat brain tumors
Stem cell Sources Tumor type References
MSC Bone marrow Glioblastoma [27-31]
Adipose Glioblastoma [27,28,30-32]
NSC Fetal brain Medulloblastoma, Glioma [33-36]
Shown are two different types of stem cells, obtained from varied sources to
treat brain tumors.
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vasive and shows promise as a method of treatment. In
an experimental mouse model, drug-loaded MSCs were
delivered through the intranasal route and resulted in ef-
fective treatment of glioma [21,22]. Other varied ap-
proaches range from physical to chemical methods to
evade the hurdles associated with the BBB to deliver
drugs. An example of physical bypass of the BBB in-
volved the use of surgical implantation of cells and drug-
soaked discs designed to release the drugs in a time-
dependent manner. This method has the advantage of
allowing very specific drug dosing by placing the cells
near or within the tumors or lesions. The disadvantage
of this method is the disruption of BBB integrity caused
by the surgery. In another physical approach, drug or
stem cells are released outside the BBB while tight BBB
junctions are loosened by ultrasound [23]. This has the
advantage of temporarily affecting BBB integrity, but
leaves the dosage to be empirically determined. The tight
intercellular junction requires that molecules are modi-
fied for traversing the BBB. Since the junction heavily fa-
vors lipophilic molecules, drugs are chemically modified
by lipidation and glycosylation [24]. An alternative ap-
proach is to load the drugs in liposomes for passage
through the BBB [25,26]. These strategies would allow
for control of the drugs passing into the brain. However,
increased amount of drugs into the brain can be hazard-
ous because passage out of the BBB would be subjected
to the same constraints as passage into the BBB. Thus,
there will be an accumulation of drug metabolites that
could lead to toxicity over time.
In the future, investigation into novel pathways regu-
lating BBB permeability may lead to new strategies for









Loading on to liposomes Drugs
The table shows the use of specific methods to deliver cells and drugs to the
brain [21,22].that BBB permeability is subject to alterations in some
diseases. For example, neurodegenerative diseases such
as neuropsychiatric systemic lupus erythematosus and
Parkinson’s disease have been reported to show in-
creased permeability of the BBB [37,38]. The BBB can
also be altered under non-disease conditions to facilitate
the immune response. This could occur by the involve-
ment of components associated with the BBB such as
pericytes. The pericytes can respond to changes in the
microenvironment by changing their structures and
shapes to modulate BBB permeability [39]. If it were
possible to mimic the pathways responsible for opening
the BBB for immune response, methods could be devel-
oped to trick the BBB into temporarily opening up to
allow delivery of cellular therapies.
Viral gene therapy
This section discusses approaches involved in the use of
engineered viruses to deliver enzymes that can convert
prodrugs into toxic metabolites. Viruses preferentially
infect rapidly dividing tumor cells. Figure 1 shows how
virus-containing genes could be packaged for cancer
therapy. Here, the non-dividing nature of neural cells
would be spared by the infection to deliver the virus. A
commonly used method is to combine the gene delivery
system with a gene that expresses the enzyme, thymidine
kinase, followed by ganciclovir treatment. The infected
cells are able to translate the enzyme thymidine kinase,
which phosphorylates ganciclovir to ganciclovir triphos-
phate. As a result, only the infected, rapidly dividing
cells, are killed by the toxic metabolites and apoptosis is
induced both in transduced cells and also adjacent divid-
ing cells (“bystander effect”) [40]. Numerous preclinical
and phase I/II studies have investigated this procedure
and showed promising results. In an in vivo study using
a rat model of cerebral glioma, fibroblasts carrying the
herpes simplex virus type 1 thymidine kinase (HSV-tk)
gene through retroviral vector were stereotactically
injected and subsequently treated with ganciclovir (GCV)
to produce a therapeutic response [41]. Clinically, a pilot
trial using HSV-tk-containing adenoviruses (AdV-tk) and
GCV in 13 patients with recurrent malignant brain tu-
mors showed acceptable toxicity [42].
A phase Ib trial with relatively few patients (n = 12)
who were newly diagnosed with malignant glioma re-
ceived AdV-tk via tumor bed injection at time of sur-
gery. This was followed by valaciclovir with overlapping
radiation therapy, then treatment with the chemothera-
peutic temozolomide. The treatment showed no signifi-
cant toxicity and resulted in survival of 33% at 2 years
and 25% at 3 years. The patient-reported quality of life
was stable or improved after treatment. Significant T-
cell inflammatory infiltrate was found in four re-resected
tumors, implying long-lasting immune stimulation [43].
Figure 1 Use of oncolytic viral transfer into cancer cells. The figure is a schematic representation of viral transfer to target rapidly dividing
cancer cells. The gene of interest is integrated in the viral genome (left). The engineered virus is administrated and infects rapidly dividing cells,
like cancer cells (center). Infected cells then have integrated DNA of the gene of interest that was carried by the virus, resulting in their
expression (right).
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treat initial and recurrent high-grade gliomas showed a
significant improvement in survival when compared with
historical controls. However, the subsequent randomized
phase II trials did not show any statistically significant
improvement in survival [44]. Based on these conflicting
results in preclinical and phase I/II studies, a phase III
study was conducted in adults with previously untreated
GBM [45]. This trial utilized HSV-tk and GCV gene
therapy as an adjuvant to surgical resection and radi-
ation. The trial involved 248 patients that received either
surgical resection and radiotherapy, or surgical resection
and radiotherapy plus adjuvant gene therapy at the time
of surgery. The experimental treatment was confirmed
to be safe; however no difference was noted for overall
survival or disease progression.
A more recent phase III study (n = 250) on the clinical
use of Adenovirus-mediated gene therapy with sitimagene
ceradenovec (replication-deficient adenovirus) followed by
intravenous GCV (ASPECT trial) has been conducted
[46]. The study compared standard of care (surgical resec-
tion followed by radiotherapy and chemotherapy) with
perilesional injection of sitimagene ceradenovec followed
by GCV. The median time to death or re-intervention was
longer in the experimental group (p = 0.006) and, in a sub-
group of patients with non-methylated methylguanine-
DNA methyltransferase (MGMT) the hazard ratio (HR)
was 1.72 (95% CI 1.15-2.56; p = 0.008). However, there
was no difference between the two groups in terms of
overall survival. One possible explanation for the discord-
ant results observed in the studies is the variable gene de-
livery and transduction rate in the tumor cells, which hasbeen rarely measured. This observation encourages fur-
ther efforts focused on the optimization of drug delivery
administration [47].
Use of stem cells in glioblastoma treatment
Neoplasias, including gliomas, are heterogeneous dis-
eases. There is overwhelming in vitro and in vivo evi-
dence that a subpopulation of cancer stem cells (CSCs)
initiates and sustain tumor growth, resulting in tumor
masses with heterogeneous malignant cells [48]. It has
also been suggested that a subpopulation of glioma CSCs
(gCSCs) may be responsible for the resistance to stand-
ard therapy. Eradication of the gCSCs could lead to sig-
nificant improvement in patients’ outcomes [49].
Targeting cancer stem cells (CSCs)
Targeting CSCs could be most efficient to prolong the sur-
vival of cancer patients. Several microRNAs, such as
miRNA-145 and oncomiR-138, have been identified for this
purpose. The oncomiR-138 is considered to be a molecular
signature of gCSC and has been targeted by functional in-
hibition in vitro, resulting in decreased tumorigenesis and
impairment of gCSCs growth [50]. In vitro studies showed
a tumor suppressive effect of miRNA-145 in glioblastoma
[51]. The suppressive effects of miR-145 occur by its ability
to decrease the expression of stem cell-linked genes within
the CD133 expressing CSC-like cells [51]. Ectopic delivery
of miR-145, in combination with radiotherapy and chemo-
therapy, improved survival in an experimental model of
glioblastoma [51]. The inhibition of the Notch pathway
through gamma-secretase inhibitors has also been experi-
mentally studied as a targeted treatment for gliomas [52].
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impregnated, polymer bead delivery system. This treatment
method blocked tumor growth and prolonged the survival
of a small cohort of mice.
Stem cells in gene and drug delivery
Studies are proposed with NSCs as a possible cellular
vehicle to deliver suicide genes to tumors. The advantage
of this approach is that NSCs are tumor tropic. The
tropic effects are likely facilitated by the production of
several chemoattractants by glioma cells, such SCF-1 or
MCP-1 [53]. Tables 1 and 2 show a snapshot of how
drugs can be delivered to brain tumors with the use of
stem cells. Also shown in Table 2 are the different ap-
proaches to find the most efficient method to deliver the
drug-loaded stem cells to the brain.
There are few reports describing the use of NSCs to de-
liver the enzyme cytosine deaminase (CD), followed by
treatment with 5-Flucytosine (5-FC). 5-FC can be con-
verted by CD to the cytotoxic compound 5-fluorouracil
(5-FU), which selectively targets tumor cells, with minimal
toxicity to the surrounding healthy tissues [1]. Clinical
trials using a similar approach are ongoing [54]. Pro-
grammed self-destructive NSCs have also been used as
a delivery tool for pH-sensitive Mesoporous Silica
Nanoparticles-doxorubicin (MSN-dox); the NSCs migrate
to the tumor site, eventually undergo apoptosis and re-
lease the MSN-dx to the surrounding gCSCs. [55]. MSC
have been used in several experimental models as an
efficacious tool for drug delivery. Delivery of soluble
(s)-TRAIL via MSCs has been shown to induce apoptosis
in glioma. Mice were implanted with a mix of gCSCs and
S-TRAIL-expressing MSCs or a mix of gCSCs with GFP-
expressing MSCs as control. Real time imaging showed a
significant reduction in tumor burden in animals im-
planted with MSCs expressing s-TRAIL as compared to
controls [56].
Recent studies showed a role for miR-9 in the expres-
sion of the drug efflux transporter, P-glycoprotein in
TMZ-resistant GBM cells [2]. MSCs loaded with anti-
miR-9 were able to deliver the drug through exosomes
thereby re-sensitizing the GBM cells to TMZ [2]. MSCs
were used to deliver the CD suicide gene in vivo [27]. In-
tracerebral inoculation of engineered MSCs after glio-
blastoma surgical resection resulted in a curative
outcome in a significant number of mice [27].
Marrow-isolated adult multilineage inducible (MIAMI)
cells, which are believed to be a subset of MSCs, have
been used to deliver lipid nanocapsule loaded with an
organometallic complex [28]. In vitro and in vivo studies
indicated that this type of drug delivery resulted in cyto-
toxic effect on the glioma cells [28]. MSCs, engineered
to express a single-chain antibody to EGFRvIII, were co-
injected with EGFRvIII (+) glioblastoma in a xenograftmodel. The MSCs-EGFRvIII showed significant increase
in the survival of the mice as compared to the controls
injected with glioma cells alone [57].
Oncolytic viruses
Another possible approach to treat brain tumors in-
volves the use of oncolytic viruses. These viruses pre-
serve the ability to replicate, selectively amplifying in
cancer cells to cause cytotoxicity. The oncolytic virus
can also activate and stimulate the natural immune re-
sponse to target infected cells. One example of a widely
used oncolytic virus is herpes simplex virus (HSV), pri-
marily because of its cytotoxicity and ability to induce a
strong immune response [58].
Several phase I/II studies investigated this technique
using various engineered viruses, such as HSV, adenovirus,
retrovirus and others, and showed overall safety, low rate
of complications, and promising effects [59-61]. Cheema
et al. combined oHSV and IL-12 to enhance the immune
response and at the same time prevent angiogenesis [62].
The transgenic oHSV (G47Δ-mIL12) showed a significant
increase in survival, decreased neovascularization, de-
creased VEGF expression, and increased production of
angiostatic IP-10 (CXCL10). The efficacy of the transgenic
oHSV was markedly reduced in athymic mice, suggesting
a direct effect of T-cell stimulation with IL-12.
Anti-cancer vaccines and stem cells
The use of anti-cancer vaccines has been studied for the
treatment of several solid tumors, resulting in discordant
results [63]. These therapies re-sensitize and enhance
the natural immune response of the host against tumor
cells. In the absence of the vaccine the tumors can evade
the immune response.
One method involves the use of dendritic cells (DCs)
from patients for sensitization to the tumor’s unique an-
tigens. The DCs are then reinfused in the patient, where
they can activate cytotoxic T-cells against the tumor
cells. Several phase I and II studies showed feasibility
and safety of this approach in the treatment of gliomas,
with some encouraging results [64-66]. Another easier
approach to cancer vaccine is the use of formalin fixed
tumor cells, collected at tumor’s resection time, as a
stimulant for immune response. This approach has been
studied in phase I/II studies with promising results [67].
The combination of cancer vaccine with EGFR inhibitors
has also been explored in a phase II study, showing
safety and increased survival [68].
Targeting the subpopulation of glioma Cancer Stem
Cells (gCSCs) through immunotherapy could lead to the
eradication of gCSCs. This particular subpopulation of
cells is therefore the ideal candidate for vaccine therapy.
Ji et al. took advantage of CD133, a proposed marker of
gCSCs, as a target to stimulate cytotoxic T-cells (CTLs)
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were generated and pulsed with autologous DCs. The
CTLs efficiently recognized the CD133 epitopes and
were specifically able to lyse CD133+ gCSCs in vivo.
Chimeric antigen receptor
Chimeric antigen receptor (CAR) T-cells were first de-
veloped in an attempt to expand the therapeutic poten-
tial of effector lymphocytes in adoptive T-cell transfer, a
term first coined in the 1950s [70]. In a landmark study,
the single-chain of an Fv (scFv) antibody molecule was
fused to the γ chain of the Fc receptor or to the ζ of the
CD3 complex, creating T cells with antibody type speci-
ficity and subsequent IL-2 signaling leading to target cell
lysis [71]. This target-binding site displays an affinity
much higher than TCRs, and in addition is MHC inde-
pendent, avoiding tumor escape mechanisms secondary
to MHC loss variants. The advancements in the field to
characterize “designer lymphocytes” provide a scaffold
for cell-based immunotherapies. Here we discuss the
CAR T-cells as a method of immunotherapy for brain
tumors because these cells show enhanced efficiency to
enter the brain (Figure 2). Indeed, there are ongoing
studies to use CAR T-cells to EGFR, a common receptor
on glioblastoma [72].
Over the years, CARs have been engineered and ma-
nipulated to achieve more targeted and potent effects.
The need for this became clear upon further under-
standing of activating ligands on antigen presenting
cells such as CD80 and CD86 that bind to the co-Figure 2 Relative efficiency of drug delivery in cells or alone. Left: Sho
protection of the BBB. Right: Shows the potential to increase the efficiency
is the efficiency of CAR T-cells to enter the brain.stimulatory receptors found on T-cells including, but
not limited to CD28 [73]. Further focus turned towards
incorporating co-stimulatory signals into the domain in
order to prevent T-cell apoptosis or anergy [74,75]. This
has otherwise led to the development of second and
third generation CARs with greater effects than previ-
ous generations.
The advantages of CAR therapy are many including
HLA-independent recognition of target antigens and the
ability to rapidly deliver a large population of tumor
antigen-specific T-cells. However, there are important
disadvantages that must be addressed, including ‘on tar-
get/off tumor’ effects, explained by antigen similarities
that may be shared by normal cells and tumor cells, and
cytokine-release syndrome.
Cytokine-release syndrome is driven by pro-inflammary
cytokines such as IFN-γ, TNF-α and IL-2 [76,77] or more
recently described, IL-6 [78]. The effects of IL-6 was dem-
onstrated with studies using toclizumab (anti IL-6 recep-
tor monoclonal antibody) in glucocorticoid resistant
GvHD [79]. Cytokine-release syndrome seems to be re-
lated, however with T-cell expansion as patients present
clinically with fever, variable degrees of myalgias, nausea
and anorexia and with complications that ranged from
hemodynamic or respiratory instability [76].
Medically, there are clinical manifestations that limit
the use of CAR therapy. CAR therapy is contingent on
the immunogenicity of the target cells. The growing field
of cancer stem cells (CSCs) showed that they should be
the target cells. The identification of markers on CSCsws the low efficiency of drugs entering the brain due to the
of drug delivery when the drug is applied within MSCs. Center: Shown
Table 3 Cancer targeting agents delivered by stem cells
for glioblastoma
Drug/gene Stem cell Targeting method References
Cytosine
deaminase (CD)




CD MSCs Indirect, via conversion
of the prodrug. 5-FC
[27]
MSN-dox NSCs Direct [55]
Soluble TRAIL MSCs Direct [56]
miR-9 MSCs Direct [2]
Fc-diOH-LNC MIAMIs Direct [28]
Shown are representatives methods by which drug/gene/RNA can be used in
stem cell delivery system for the treatment of glioblastoma. Direct method
indicates that the stem cells release the drug, which interacts with the cancer
cells for cytotoxic effects. Indirect effects are indicated when an enzyme is
delivered in the stem cells for the local conversion of a prodrug to its
active form.
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munogenic are CSCs? There are also concerns to the
fate of CAR cells upon entering the tumor microenvir-
onment. Lastly, most data pertains to hematological ma-
lignancies; yet some data, although limited with modest
or null results, have been done on solid tumors, includ-
ing neuroblastomas [80].
There are recent advances with promising results in
CAR therapy. The mechanisms behind cytokine-release
syndrome and its associated neurotoxicities must be ad-
dressed. These limitations may further be explored with
future studies that include greater power. This may pave
the way for engineering of other cells, as CAR modifi-
able cells are not limited to T-cells, but also include, but
are not limited to NK cells, iNKT cells.
Conclusion
Glioblastoma’s aggressive behavior seems to be deter-
mined by the extreme heterogeneity of this tumor,
which can be sustained by gCSCs. The CSCs can gener-
ate, re-generate and maintain tumor growth. The chal-
lenges related to the treatment of glioblastoma are
represented in the first place by the BBB, which physic-
ally isolates the brain from the rest of the body, causing
difficult delivery of chemotherapeutics and reducing the
access of cells of the immune system. Figure 2 shows
the relative efficiency of delivering drugs directly or
through stem cells. The stem cells show promise to
enter the brain with higher efficiency to directly deliver
the drugs to brain.
Glioblastoma is indeed often able to evade the natural
host’s immune response. Studies focusing on successful
delivery of therapeutics have been conducted to deter-
mine if the permeability of BBB can be modulated to en-
hance the transport of drugs to the brain. Further
studies focused on the regulatory pathways of the BBB’s
permeability could allow delivery of targeted therapies in
specific time frames.
Different types of stem cells have been studied as a
method of optimal delivery of suicide genes and drugs,
due to their unique ability to migrate to the tumor bed
with adequate specificity (Table 3). MSCs can be rela-
tively easily harvested and expanded, however concerns
regarding the potential for transformation needs to be
thoroughly addressed [81].
Gene therapy has been broadly studied for glioblastoma,
and various techniques for gene delivery involving the use
of stem cells as transporters, have been investigated with
promising results in vivo and in preclinical studies; unfor-
tunately phase III clinical trials failed to demonstrate a
clear advantage of experimental therapies in terms of OS.
This could be explained by low delivery rate and/or incon-
sistent levels of transductions of the drugs, therefore
further research focused on improvement of deliverymethods could potentially bring significant improvements
to glioblastoma gene-based treatments [47].
Finally, great hope is represented by strategies based
on the enhancement of natural host immune response,
which is frequently evaded by the tumor: anti-cancer
vaccines targeting gCSCs would theoretically allow the
eradication of this cell subpopulation, likely responsible
of recurrence and resistance to chemotherapy. This
study addresses the use of CAR T-cells, which shows
promise. Its inclusion in this brief review is mainly due
to the relative ease to enter the brain [72].
The use of MSCs or NSCs as a delivery tool for either
specific genes or drugs has been explored in vitro and
in vivo showing promising results in terms of tumor
cells cytotoxicity and increased survival in animal
models. These methods clearly offer enormous advan-
tages for the potential treatment of brain tumors, being
able of targeting almost uniquely cancer cells. Few clin-
ical trials addressing the feasibility and safety of these
approaches are ongoing (Table 2).
In conclusion, as an extreme heterogeneous disease,
complicated by the peculiar localization in a selectively
protected environment, glioblastoma is a disease that
needs to be approached from different angles, keeping in
mind the unique limits and potentials of the organ from
which it raises from. These features, even though ex-
tremely challenging, offer potential starting points for
future research.
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